Zhejiang Pharmaceutical: Subsidon new code biological B round capital increase of strategic investors

On July 6, Capital State learned that Zhejiang Pharmaceutical (600216.SH) announced by A -share company, the second phase of the new code biological B -increasing capital of the subsidiary of the new code biological B, the second phase of the investment industry investment fund (limited partnership), Li'an Xinhao Co., Ltd., Ten strategic investors including Suzhou Li Run Equity Investment Center (limited partnership) and Rongtu shares.

Investors intend to increase capital increases to target companies with a total capital increase of 400 million yuan or equivalent USD, and subscribe to the target company's new registered capital of RMB 3.626 million (the remaining capital increase is included in the capital reserve of the target company), After obtaining the capital increase, the target company was about 12.9454%of the equity.

The purpose of this capital increase aims to expand the capital strength of the target company and optimize the equity structure. All parties have negotiated through friendly consultations to achieve this transaction. Combining their own experience in enterprise management business, focusing on the development strategy of the target company, consolidate the core competition of the target company force.

Zhejiang Pharmaceutical said that the capital increase meets the company's strategic development and management needs, which is conducive to promoting the company's sustainable development. This transaction follows the principles of openness, fairness, and impartiality, and the pricing is fair and reasonable. It is in line with the interests of the company and all shareholders. There is no situation that harms the interests of the company and small and medium shareholders.

This capital increase will not have a significant impact on the company's business development and profitability. The company is still the actual controller of the company, which will not lead to changes in the scope of the company's merger statement.

- END -